Pharmaceutical care of five cases of hypophosphatemic osteomalacia secondary to renal tubular damage caused by adefovir
- Author:
Zhi-Hui TANG
1
Author Information
- Publication Type:Journal Article
- Keywords: Adefovir dipivoxil; Clinical pharmacist; Pharmaceutical care; Phosphorus osteomalacia; Tubular damage
- From: Chinese Pharmaceutical Journal 2015;50(8):727-730
- CountryChina
- Language:Chinese
- Abstract: OBJECTIVE: To summarize the outcomes and clinical features of hypophosphatemic osteomalacia secondary to renal tubular damage caused by adefovir and put forword the key points of pharmaceutical care for these patients. METHODS: Literature was retrieved about hypophosphatemic osteomalacia secondary to renal tubular damage caused by adefovir in recent years. Combining the clinical situations of five patients with the named damage, they were treated with complement of phosphorus preparations and monitored for related clinical indicators. RESULTS: The possible mechanisms of adefovir for causing hypophosphatemic osteomalacia secondary to renal tubular damage is gene defect. Hypophosphatemic osteomalacia often occurrs in patients taking small doses (10 mg · d-1) of adefovir for more than one year. The symptoms aggravate over time. By withdrawing adefovir or switching to other antiviral drugs and giving syptomatic treatment with phosphorus, calcium, and vitamin D supplements and other measures, good prognosis was achieved. CONCLUSION: Hypophosphatemic osteomalacia secondary to renal tubular damage caused by adefovir is lack of specific clinical features, which is easy to be misdiagnosed, therefore attention should be paid by clinical professionals.
